IL-2 has been shown to be effective in cancer therapy.186 However, the half-life of IL-2 is short (10–85 min in serum),187 and therefore, it must be repeatedly administered in short intervals to maintain efficient bioavailability, which limits its clinical use. Here, IL2 is linked to cancer.